HK Stock Market Move | Mawei Biosciences-B (02493) rose more than 3%. Its subsidiary MaweiVision has reached a strategic cooperation with Womow Biotech, focusing on the fields of ophthalmic inflammation and eye immunity.

Maiwei Biosciences-B (02493) rose more than 3%, as of press time, it increased by 2.72%, reaching HK$26.48, with a turnover of HK$6.4846 million. On the news front, on June 16th, according to Maiwei Biosciences' official WeChat account, the company announced that its holding subsidiary Maiwei Vision has reached a strategic cooperation with the leading domestic eye small molecule drug research company, Weimou Bio. The two parties will focus on the unsatisfied clinical needs in the two core directions of eye inflammation and eye immunity and carry out comprehensive and in-depth cooperation. According to the introduction, Maiwei Biosciences have a variety of retinal products, including 9MW0211 anti-VEGF monoclonal antibody innovative drugs, adalimumab biosimilar drugs, abatacept biosimilar drugs, covering mature drugs in the fields of eye immunotherapy, retinal disease drugs, dry eye, and ocular surface. Weimou Bio is a clinical-stage innovative drug company focusing on ophthalmic treatment, which has established a unique ophthalmic innovative drug research and development platform, and several independently developed innovative drug products have entered the clinical stage.